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Nitric Oxide Synthase and Antimicrobial Armature of
Human Macrophages
To the Editor-Recently Schneemann et al. [I] showed that in
human mononuclear phagocytes high-output nitric oxide syn-
thase (NOS) is not inducible by a variety of stimuli, including
interferon-y, endotoxin, and tumor necrosis factor-a, known
inducers of NOS in other human and in murine cells, including
macrophages. The conclusion that NOS is not a constituent of
the antimicrobial armature of human mononuclear phagocytes
agrees with earlier speculations by us and others, but there are
still some reservations.
Because of their enzymic repertoire, human macrophages
differ significantly from other human cells and particularly from
murine cells; Although high activity of 6-pyruvoyl-tetrahydrop-
terin-synthase is constitutively present in all these cells, activity
is significantly lower in the human macrophage [2]. For that
reason, human macrophages produce on stimulation with inter-
feron-v a 50-fold excess of neopterin derivatives compared with
the amount of biopterin derivatives including tetrahydrobiop-
terin (BH4). In agreement with this in vitro finding, increased
concentrations of neopterin are detectable in patients with a
variety of disorders associated with stimulated cellular immu-
nity, such as allograft rejection, autoimmune disorders, and hu-
man immunodeficiency virus infection [3], whereas biopterin
concentrations change rarely and little. The ratio ofneopterin to
BH4 lies strongly on the side ofBH4 in other human cells, such
as fibroblasts and endothelial cells, or in murine macrophages,
in which at least 50-fold more biopterin derivative than neop-
terin (or no neopterin at all) is detectable [2,4].
Thus. there is not a complete lack of BH4 in human macro-
phages as described by Schneemann et al. [I] but a relative defi-
ciency. Moreover, it has been demonstrated that deficiency of
BH4 cannot explain the inability to detect nitric oxide (NO)
production by human macrophages, because exogenous admin-
istration ofBH4 did not normalize the output ofNO [5]. Still the
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Reply
To the Editor-We appreciate the comments of Fuchs et al. [I]
in response to our article. We agree that there are indeed funda-
mental differences in biopterin synthesis, arginine metabolism,
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question remains whether the cytokine profiles used so far to
stimulate NOS in human macrophages are incomplete and the
stimuli necessary for NOS induction are more distinct from the
murine system or from other human cells. as was anticipated.
The question arises of why the diversity exists of pteridine
biosynthetic pathways between human macrophages and other
human cells and especially murine macrophages. Recently, in
vitro experiments showed that neopterin can enhance effects
mediated by cytotoxic substances, such as hydrogen peroxide or
hypochloric acid, at a physiologic pH. Signal intensity in a lu-
minol assay and antimicrobial toxicity ofhydrogen peroxide and
hypochloric acid were enhanced up to IOO-fold by addition of
neopterin [6]. The data suggest that neopterin can enhance cyto-
toxicity in general. and it may have a pivotal role in the modula-
tion of radical-mediated effector mechanisms ofmacrophages. It
thus appears that neopterin production itself can replace induc-
ible high-output NOS in the human macrophage, which retains
its ability to compete with invading pathogens. We think this is
an intriguing hypothesis to be tested.
D. Fuchs, C. Murr, G. Reibnegger, G. Weiss, E. R. Werner,
G. Werner-Felmayer, and H. Wachter
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and nitric oxide (NO) production between human and murine
macrophages. This observation was the basis of our article and
extended previous observations from our and other laboratories
(referenced in our article [2]).
The speculation of Fuchs et al. [I] that occult cytokine pro-
files might be required in human macrophages to induce NO
synthase (NOS) activity is provocative but cannot be supported
by available data, which indicate the following; Cytokine pro-
files required to induce BH4 synthesis or NO production in hu-
man cells other than mononuclear phagocytes, such as hepato-
cytes and endothelial cells, correspond to the stimuli required
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for these effects in murine cell systems [3, 4] (unpublished data).
The differences are fully expressed by non stimulated human
and murine phagocytes (i.e., without prior in vitro exposure to
cytokines). None of the following induce NO production or in-
duce changes in arginine consumption in human mononuclear
phagocytes: bacteria, a complete in vitro system ofcell-mediated
immunity, interleukin (IL)-l, granulocyte-macrophage colony-
stimulating factor, IL-4, IL-I 0, transforming growth factor-d. an
in vitro differentiation to multinucleated giant cells by pro-
longed in vitro culture, or the conventional NOS inducers lipo-
polysaccharide, interferon-y, and tumor necrosis factor-a. This
was shown in our article.
Also, in regard to the amount of detectable BH4 in human
mononuclear phagocytcs, we prefer to be specific. We maintain
that cytosolic BH4 is <0.03 pmol· mg- 1 in human mononuclear
phagocytes, which is our detection limit. Therefore, we cannot
prove that BH4 is totally lacking in human macrophages. We
wonder, however. whether the minuscule amounts ofBH4 syn-
thase activity reported in human monocyte preparations by
Fuchs et al. stem from monocytes or form contaminating lym-
phocytes in their cell preparations that produce BH4 [5, 6]. In
any event, the availability ofBH4 does not limit NO production,
as is shown in table I of our article and confirmed recently by
others ([5] in our article).
We cannot comment on the interesting speculations on neop-
terin and its possible functions, which have no direct relation to
our article.
The statement by Fuchs et al. that there is something like an
NO output that can be "normalized" in human mononuclear
phagocytes testifies to their preference for unidirectional specula-
tions. What is a normal NO output? Is it biologically important
that human mononuclear phagocytes do not produce NO on in
Low Human T Cell Leukemia Virus Type II
Seroprevalence in Africa
Colleagues-Initial surveys in sub-Saharan Africa found a high
prevalence of antibodies to human T cell leukemia virus
(HTLV) [1], later identified as predominantly HTLV-I. HTLV-
II is known to be epidemic among intravenous drug users in the
United States [2] and Italy [3] and has recently been identified
among Amerindians in the United States, Panama, and Brazil
[4]. Its presence in Africa, however, remains discrete, with only
sporadic cases having been reported. Delaporte et al. [5], while
analyzing samples with polymerase chain reaction (PCR), found
several cases of HTLV-II in Gabon, and other reported cases
have been found in pygmies from northeastern Zaire [6], pa-
tients in Somalia and Ethiopia [7], and blood donors in
Guinea [8].
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vitro stimulation by cytokines, or is it biologically important
that murine macrophages do so in vitro? Could it be that human
macrophages operative in vivo against microbes or tumors pro-
duce NO but that, possibly, murine macrophages would not?
Should we disregard all previous in vitro observations on phago-
cyte functions of mice and humans?
M. Schneemann, G. Schoedon, and A. Schaffner
Clinical Mvcologv Laboratory. Division of Infectious Diseases.
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Our study involved the collection of 11,788 serum samples
from healthy subjects (7262) and patients (4526) in several west
and central African countries. All samples were screened for
antibodies to HTLV-I using an ELISA (Abbott Laboratories,
Abbott Park, IL) or immunofluorescence test with HTLV-I-
producing HuT I02 cells. Positive samples by one or both assays
were further tested by Western blot (WB) using HTLV-I-pro-
ducing HuT I02 cells as an antigen source [9]. Samples giving at
least four virus-specific bands, including major gag antigens
p 19, p24, and env antigen gp46, were considered positive; those
giving none of these bands were recorded as negative. Interme-
diate results were classed as "indeterminate." This first part of
our study revealed that 153 (2.1 %)of7262 healthy subjects and
122 (2.7%) of4520 patients had detectable antibodies to HTLV-
I; 37 (0.5%) of7262 healthy subjects were classified as indetermi-
nate by WB (table I).
Following these initial screening tests, all positive and indeter-
minate samples were then subjected to an ELISA that used two
specific synthetic peptides (MA I and MA2) representing epi-
topes of, respectively, HTLV-I and -II core proteins as previ-
ously described [10] and also to a second WB assay with recom-
binant proteins (MTA-I and K-55) specific for HTLV-I and -II,
respectively (HTLV 2-3; Diagnostic Biotechnology, Singapore)
(table I).
